Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline Phase 2a results for TEV ‘408, its investigational anti-IL-15 monoclonal antibody for adults with celiac disease following a gluten-free diet.
Alvotech (NASDAQ:ALVO) and Teva (NYSE:TEVA) have secured a U.S. market entry date for their proposed biosimilar to Eylea® (aflibercept), AVT06, under a settlement agreement with Regeneron.
Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi (NASDAQ:SNY) announced a major clinical victory on Tuesday, revealing that their investigational antibody, duvakitug (formerly TEV-574), successfully maintained disease control in patients with inflammatory bowel disease (IBD) for nearly a full year.
Teva Pharmaceutical (NYSE:TEVA) announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea, across several major European markets, including France, Germany, Spain, and the Netherlands.
